Federation des caisses Desjardins du Quebec Buys 612,940 Shares of Pfizer Inc. $PFE

Key Points

• The Federation des caisses Desjardins du Quebec increased its holdings in Pfizer Inc. by 41.4% in the 1st quarter, owning over 2 million shares valued at approximately $53 million.
• Pfizer recently announced a quarterly dividend of $0.43, which translates to an annual yield of 7.0%, with the dividend payout ratio sitting at 91.49%.
• The company reported higher-than-expected earnings with an EPS of $0.78 for the latest quarter, exceeding estimates by 20 cents and growing its revenue by 10.3% year-over-year.

Federation des caisses Desjardins du Quebec raised its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 41.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,094,594 shares of the biopharmaceutical company's stock after purchasing an additional 612,940 shares during the quarter. Federation des caisses Desjardins du Quebec's holdings in Pfizer were worth $53,078,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in Pfizer by 0.9% during the 1st quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company's stock worth $13,257,004,000 after buying an additional 4,629,976 shares during the period. Northern Trust Corp grew its position in Pfizer by 6.8% in the first quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company's stock valued at $1,579,340,000 after acquiring an additional 3,943,397 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Pfizer by 3.5% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 39,402,619 shares of the biopharmaceutical company's stock valued at $1,045,351,000 after acquiring an additional 1,333,740 shares during the last quarter. Invesco Ltd. grew its position in Pfizer by 2.8% in the first quarter. Invesco Ltd. now owns 30,296,337 shares of the biopharmaceutical company's stock valued at $767,709,000 after acquiring an additional 838,198 shares during the last quarter. Finally, Deutsche Bank AG grew its position in Pfizer by 7.0% in the first quarter. Deutsche Bank AG now owns 28,239,197 shares of the biopharmaceutical company's stock valued at $715,581,000 after acquiring an additional 1,846,436 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer Price Performance

NYSE PFE traded down $0.23 during trading on Wednesday, reaching $24.76. The company's stock had a trading volume of 30,706,896 shares, compared to its average volume of 40,145,636. The stock has a market capitalization of $140.75 billion, a PE ratio of 13.17, a P/E/G ratio of 0.88 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The firm has a fifty day moving average of $24.83 and a 200 day moving average of $24.37. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company's quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the company earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were given a dividend of $0.43 per share. The ex-dividend date was Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. Pfizer's dividend payout ratio is 91.49%.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Bank of America lifted their price target on Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Morgan Stanley boosted their price target on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research note on Wednesday, August 6th. Jefferies Financial Group boosted their price target on Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research note on Wednesday, May 21st. HSBC decreased their price objective on Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a report on Monday, May 19th. Finally, Berenberg Bank decreased their price target on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a report on Thursday, May 29th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.